24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gilead Sciences
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:49
Israeli high-tech is strong, but how much of it will remain in Israel?
16:27
AI is giving cyber defenders a home advantage
15:45
“One plus one could equal five”: Varonis CEO on $6.3 billion Proofpoint deal
12:27
“Your org chart is your problem today”: NFX’s Gigi Levy-Weiss on re-founding companies for AI
More stories
Buzz
Most popular
Daily
Weekly
1
One-year-old Israeli AI startup with six employees acquired for estimated $100 million
2
Proofpoint to acquire Israeli-founded Varonis in $6.3 billion all-cash deal
3
Wiz billionaires emerge as frontrunners for McDonald’s Israel franchise
4
Israel’s hypersonic interceptor goes public as the U.S. and Iran race to develop advanced missiles
5
CrowdStrike in advanced talks to acquire Israeli startup Orion for $500 million
More news
Gilead Sciences
5 stories about Gilead Sciences
Investments are flowing into synthetic biology - the red-hot field that will change the world
28.07.21
|
Sophie Shulman
Synthetic biology seemed like science fiction until the arrival of the coronavirus vaccines. But now the money has begun to flow and companies are revealing remarkable inventions: from bacteria that will attack tumors to shoes made of cobwebs
ForeBio is on its way to Nasdaq at a $500 million valuation
01.03.21
|
Tzally Greenberg
The company aims to raise $100 million in an April IPO, while Pontifax and OrbiMed who previously invested $21 million for a 12.5% stake in ForeBio’s shares are expected to make a $120 million profit
Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company
10.12.17
|
Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
Kite Pharma’s Cancer Drug Gets Regulatory Nod
19.10.17
|
Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
Kite Pharma Sale Triggers Scientist Quarrel
02.10.17
|
Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur